To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
15 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Mike Kane (Lab) voted No - in line with the party majority and against the House
One of 178 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 320 Noes - 246
MP Financial Interest
Mike Kane (Labour - Wythenshawe and Sale East)
Original Source (15th April 2024)
2. (b) Any other support not included in Category 2(a)
Name of donor: Catholic Bishops Conference England & Wales
Address of donor: 39 Eccleston Square, London SW1V 1BX
Amount of donation or nature and value if donation in kind: An intern in my parliamentary office for ten months, who will receive an educational allowance of £7,000 paid directly to them, plus accommodation valued at £10,710.60, value £17,710.60
Date received: 17 October 2022 to 21 July 2023
Date accepted: 17 October 2022
Donor status: company, registration 4734592
(Registered 7 November 2022)
MP Financial Interest
Mike Kane (Labour - Wythenshawe and Sale East)
Original Source (15th April 2024)
8. Miscellaneous
A non-Executive Director of The Oxford Group, whose programmes include initiatives to develop sustainable communities; making films about conflict resolution; working to bring trust and integrity into the business and financial sectors; helping young people to find a sense of vocation. This is an unpaid role.
Date interest arose: 28 May 2022
(Registered 13 September 2022)
Written Question
Voluntary Scheme for Branded Medicines Pricing and Access
Monday 15th April 2024

Asked by: Mike Kane (Labour - Wythenshawe and Sale East)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to section 6.26 of the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, whether her Department has been allocated additional resources to consider exceptional circumstances.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.

Written Question
Voluntary Scheme for Branded Medicines Pricing and Access
Monday 15th April 2024

Asked by: Mike Kane (Labour - Wythenshawe and Sale East)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the guidance entitled 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, published on 20 November 2023, what steps her Department is taking to apply the provisions of section 6.26 on exceptional circumstances.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

In the vast majority of instances, payments required under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth will be affordable for companies, or can be mitigated by standard price increase processes. In exceptional circumstances only, the scheme allows companies to apply to increase their National Health Service list price, and for older medicines to reduce their top-up payment percentage, even when their wider portfolio is otherwise profitable. To qualify, a product must be demonstrably uneconomic to supply, there must be clear evidence that supply disruption would otherwise occur, and this disruption must have a negative impact on patients or the NHS. The Department already has processes and committees to consider applications for exceptional circumstances, established under previous pricing schemes.

Division Vote (Commons)
22 Mar 2024 - Hunting Trophies (Import Prohibition) Bill - View Vote Context
Mike Kane (Lab) voted Aye - in line with the party majority and in line with the House
One of 20 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 49 Noes - 0
Speech in Commons Chamber - Thu 21 Mar 2024
Oral Answers to Questions

Speech Link

View all Mike Kane (Lab - Wythenshawe and Sale East) contributions to the debate on: Oral Answers to Questions
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Mike Kane (Lab) voted Aye - in line with the party majority and against the House
One of 154 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 218 Noes - 305
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Mike Kane (Lab) voted Aye - in line with the party majority and against the House
One of 151 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 217 Noes - 305
Division Vote (Commons)
19 Mar 2024 - Trade (Comprehensive and Progressive Agreement for Trans-Pacific Partnership) Bill [Lords] - View Vote Context
Mike Kane (Lab) voted Aye - in line with the party majority and against the House
One of 152 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 219 Noes - 306